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erozygosity predicts increased fetal loss (28, 29) . Acquired activated protein C resistance, independent of the factor V Leiden mutation, is also a risk factor for RPL (30) .
Women with polycystic ovary syndrome (PCOS) have high level fetal losses (>50%), particularly in the first trimester (31) (32) (33) (34) thought to be caused in part by hypofibrinolysis mediated by the 4G4G mutation of the plasminogen activator inhibitor-1 gene and high levels of its gene product, plasminogen activator inhibitor-1 activity (PAI-Fx) (31, (35) (36) (37) (38) . PCOS is associated with insulin induced, metformin-reversible, high PAI-Fx (31, 39, 40) .
Because metformin sharply reduces spontaneous abortion (SAB) in women with PCOS (31) (32) (33) (34) , understanding of any concurrent roles of thrombophilia, hypofibrinolysis, and PCOS in women with RPL might, speculatively, be useful in setting the groundwork for combined enoxaparin (41) (42) (43) (44) (45) (46) metformin (31) (32) (33) (34) therapy in pregnant women with PCOS-RPL and the G1691A factor V Leiden and PAI-1 4G4G mutations.
There is no evidence for a conjoined inheritance of the factor V Leiden mutation and PCOS (47, 48) . Women with PCOS are not more likely than normal women to have resistance to activated protein C (47) . Tsanadis and colleagues did not find a significant enrichment with thrombophilia in 30 women with PCOS compared to normal controls (48) . Placental thrombosis may be a major final common pathway in repeated pregnancy wastage (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (41) (42) (43) (44) (45) (46) 49, 50) .
Two controlled clinical trials (51, 52) have demonstrated the efficacy of heparin plus lowdose aspirin (vs. low-dose aspirin alone) in antiphospholipid antibody syndrome (53) , an acquired thrombophilia associated with recurrent fetal loss and severe complications (preeclampsia, fetal growth retardation, placental insufficiency). In women with consecutive recurrent miscarriages and hereditary thrombophilia, Carp and colleagues (54) compared 40 women with hereditary thrombophilia treated with daily enoxaparin (40 mg/day) and 48 not treated; 26 of 37 (70%) pregnancies in treated patients resulted in live births compared to 21 of 48 (44%) in untreated patients (p <. 02). Regrettably, to date, there have been no published enoxaparinplacebo-controlled clinical trials in women with familial thrombophilia-hypofibrinolysis to optimally document safety and efficacy of thromboprophylaxis in fetal salvage. In most studies, pregnancy outcome is compared to antecedent pregnancies in the same women, without thromboprophylaxis (41) (42) (43) (44) (45) (46) 49, 55) . This model is, unfortunately, open to the criticism that the improved pregnancy outcomes on thromboprophylaxis simply reflect the phenomenon of regression toward the mean (56) , and that any placebo intervention would necessarily be more successful than the previous serial pregnancy losses.
Because thrombophilia, hypofibrinolysis, and PCOS are associated with recurrent RPL and SAB alone and concurrently, our specific aim was to prospectively assess the efficacy-safety of combined enoxaparin-metformin in women with PCOS with one or more previous SAB, thrombophilia, and/or hypofibrinolysis. To deal with the otherwise high first trimester SAB rate in PCOS, we prospectively treated with metformin (1.5 to 2.55 g/day) before and throughout gestation, and to deal with thrombophilia and/or hypofibrinolysis we concurrently treated with enoxaparin (60 mg/day) throughout gestation. Main outcome measures included pregnancy outcomes in women receiving enoxaparin and metformin, and safety and efficacy of the enoxaparin-metformin therapy.
MATERIALS AND METHODS

Study Design, Subjects
This study followed a protocol approved by the Jewish Hospital Institutional Review Board, with written informed consent. To enter the study, women had to be free of the following known etiologies for RPL and SAB: anatomic uterine abnormalities (by sonogram, hystero-salpingogram), cervical incompetence, poorly controlled diabetes mellitus, and hypothyroidism (57) . The current report was a consecutive case series of 24 white women, free of the previous exclusionary criteria, 23 of whom had previous pregnancies, with 22 referred with one or more pregnancy losses (seven with RPL [≥ three consecutive losses before 20 weeks' gestation]), and one with HELLP syndrome. All pregnancies studied (retrospective historical, prospective on enoxaparin [Aventis Pharmaceuticals, Bridgewater, NJ]) were conceived with the same male partners, thus avoiding differing male partner chromosomal translocation or sperm DNA fragmentation that might have played a role in RPL. No exclusions were made for parental karyotyping abnormalities (57) , preferential X chromosome inactivation (58), immunoglobulin A anti-beta 2-glycoprotein antibodies (59), or cytokine promoter abnormalities (60) most of which had never been analyzed after previous pregnancy losses. (Table 1) were made in the non-pregnant state in both patients and controls, with subjects not taking hormones or corticosteroids that could affect serologic measures of coagulation. Fasting blood was obtained for polymerase chain reaction (PCR) and serologic measures of coagulation in the early morning with subjects in the seated position, using previously published methods (23, 61, 62) .
All coagulation measures
Our primary source of referrals for evaluation of RPL and SAB has been women with PCOS (31) (32) (33) 38) . Hence, it was not surprising that of 23 women referred because of one or more pregnancy losses or HELLP syndrome, and the one case with known high anticardiolipin antibodies (no. 4, Table 1 ) who had not been able to conceive, all 24 were subsequently shown to have PCOS ( Table 2) .
Clothed weight (without shoes or overclothes) and height were measured at study entry. Reproductive history, diagnosis of previous gestational diabetes mellitus, and menstrual status in the previous year were recorded. At entry, before conception, after an 8-hour overnight fast, systolic and diastolic blood pressure, glucose, HgA1C, blood urea nitrogen, creatinine, lipid profile, endocrine status (estradiol, progesterone, leutenizing hormone, follicle-stimulating hormone, androstenedione, dihydroepiandrosterone, testosterone, sex hormone binding globulin), serum insulin, and lactic acid were measured, as previously described (31) (32) (33) 38 ). The homeostasis model assessment formulas (HOMA) (63) were used to calculate insulin resistance (fasting insulin [uU/mL] × glucose [mmol/L]/22.5) and B-cell function (20 × fasting insulin/[glucose-3.5]). At entry, before conception, 17-OH progesterone, prolactin, thyroxine, thyroid-stimulating hormone, and cortisol were measured to rule out diseases that can mimic PCOS or affect its presentation (31) (32) (33) 38) .
For a median of 5 months before conception, women with a body mass index (BMI) less than 25 kg/m 2 or greater than or equal to 25 kg/m 2 , respectively, were given a 2000 or 1500 calorie/day, high protein (26% of calories), low-carbohydrate (44%) diet. Calorie restrictions were dropped after conception, but continued adherence to the low carbohydrate, high protein distribution of calories was encouraged. For a median of 5 months before conception and throughout gestation, 11 women received metformin, 850 mg, three times per day with meals, and 13 received 500 mg three times per day (31) (32) (33) .
Metformin (1.5 to 2.55 g/day) (Bristol-Myers Squibb Company, Princeton, NJ) was continued throughout pregnancy (31) (32) (33) .
After documentation of coagulation disorders, self-administered, subcutaneous enoxaparin, 60 mg/day was started immediately after confirmation of pregnancy, before week 4 of gestation. Before and throughout pregnancy, 1 mg folic acid/day was given to help prevent neural tube defect (spina bifida).
At monthly follow-up visits throughout pregnancy, weight, blood pressure, complete blood cell count and platelet count, fasting blood glucose, and HgA1C were measured.
Diagnosis of Polycystic Ovary Syndrome
The diagnosis of PCOS was made on the basis of chronic oligomenorrhea and clinical hyperandrogenism (hirsutism [Ferriman-Gallwey (64) score ≥ 7], severe acne), and/or biochemical hyperandrogenism (high total or free testosterone, androstenedione, or dihydroepiandrostendione) (31-33,65,66) ( Table 2 ). Exclusionary criteria included serum creatinine greater than 1.5 mg/dL, type 1 diabetes mellitus, type 2 diabetes mellitus on pharmacologic therapy, pituitary insufficiency, persistent hyperprolactinemia, and congenital adrenal hyperplasia (31) (32) (33) 65, 66) . Having selected the cohort on the basis of previous PCOS diagnostic criteria (31) (32) (33) 65, 66) , we also examined the diagnosis of PCOS in the subset of 19 women having polycystic ovaries documented by pelvic ultrasound and/or laparotomy ( Table 2 , bottom four rows), using criteria of the very recent (July 2003) ESHRE/ASRM consensus conference on PCOS (67, 68) . Of these 19 women, 17 also had measurements of the free androgen index (FAI) ( Table 2 ). Based on these new criteria, the diagnosis of PCOS ( Table 2 , bottom four rows) requires both the presence of polycystic ovaries and elevated FAI. We used a cutpoint for high FAI, 7.3 or greater, the 97.5th percentile in a general female white population (69) . We used the definitions of Laven and colleagues (68) for oligomenorrhea (bleeding intervals between 35 days and 6 months), or amenorrhea, bleeding interval greater than 6 months ( Table 2) .
Because 100% of our prospectively studied patients with PCOS conceived while taking metformin, we did not have access to a potentially informative control group, women with PCOS who conceived without metformin and did not take metformin or enoxaparin during pregnancy. HOMA insulin resistance (IR) (63) and hy- (39, 40) were not required criteria for entry into the study. Uncontrolled hypertension, gastrointestinal bleeding, or thrombocytopenia, not present in any of the 24 cases, were exclusion criteria for enoxaparin use.
Normal Controls
Thrombophilic and hypofibrinolytic gene mutations and polymorphisms in the 24 cases (Table 1) were compared with those of 93 healthy normal white female controls (61, 62) . Serologic tests of thrombophilia and hypofibrinolysis in the 24 cases (Table 1) were compared with those of 44 healthy, non-pregnant, normal white women not receiving oral contraceptives or hormone replacement therapy (61, 62) .
Coagulation Measures
Using previously published methods (23, 24, 35, 38, 61, 62) , PCR c-DNA studies were done for the thrombophilic G20210A prothrombin, G1691A factor V Leiden, and C677T methylenetetrahydrofolate reductase (MTHFR) gene mutations, for the thrombophilic PL A1/A2 polymorphism of the platelet glycoprotein gene, and for the hypofibrinolytic 4G4G polymorphism of the PAI-1 gene.
With use of previously published methods (38, 61, 62) , serologic studies for the following thrombophilic factors were performed: resistance to activated protein C, proteins C and S (total and free), antithrombin III, homocysteine, anticardiolipin antibodies IgG and IgM, dilute Russel's viper venom time (dRVVT), partial thromboplastin time, and factor VIII. Using previously published methods (61), serologic studies were done for the hypofibrinolytic PAI-Fx and Lp(a).
Statistical Methods
In blood samples obtained before starting enoxaparin or metformin, comparisons between patients and controls for measures of coagulation were made using Chi-square analyses or Fisher's exact tests (70) . In those 23 women who had previous pregnancies without metformin or enoxaparin, outcomes of previous pregnancies were compared against current pregnancy outcomes in the same 23 women on metformin and enoxaparin with McNemar's S (70) (Fig. 1) . Assuming power of 80% and alpha = .05, and using the difference in SAB in women without enoxaparin-metformin in their previous pregnancies vs. SAB in the same women on enoxaparin-metformin in the current study, we calculated what sample size would be needed for a future placebo-controlled study (placebo vs. metformin-enoxaparin) (71) .
Weight and height at birth in the 18 neonates (8 boys, 10 girls) with gestation of 37 weeks or greater (of 21 live births, three less than 37 weeks) were compared with year 2000 Centers for Disease Control male and female neonate population data for the United States (72) .
RESULTS
Coagulation Disorders
The 24 white female cases differed from 93 normal white female controls for the thrombophilic factor V Leiden mutation, 4/24 (17%) vs. 2/93 (2%), Fisher's p (p f )=. 016, and also differed for the hypofibrinolytic 4G4G polymorphism of the PAI-1 gene, 11/24 (46%) vs. 22/93 (24%), Chi-square = 4.6, p =. 031. The 24 cases also differed from the 37 (of 44 normal white female controls who had the measure) for high levels (>21.1 U/mL) of the hypofibrinolytic PAI-Fx, (eight of 24 [33%] vs. three of 37 [8%], p f =. 018). Thrombophilic factor VIII was high (>150%) in four of 18 cases (22%) vs. 0 of 21 controls, p f = .037.
As summarized in Table 1 , there were five cases with one coagulation disorder, eight with two disorders, four with three, four with four, and three with five disorders. When assessing the three major thrombophilic gene mutations (V Leiden, prothrombin gene, MTHFR) and the hypofibrinolytic 4G4G mutation, 16 of the 24 cases (67%) had one or more of these four gene mutations, vs. 36 of 93 female controls (39%), Chisquare = 6.0, p = .014, p f =. 02.
Characteristics of Polycystic Ovary Syndrome
All 24 women were white. Mean (SD) and median ages were 31 (4) and 30 years. In the year before starting metformin, nine (38%) were amenorrheic and 15 (62%) were oligomenorrheic ( Table 2 ). Most of the 24 women (88%) were hirsute (Ferriman-Gallwey (64) score ≥ 7), and 50% had severe acne ( Table 2) . Clinical hyperandrogenism (Ferriman-Gallwey (64) ≥ 7 and/or severe acne) was present in all 24 women ( Table 2) .
Of the 24 women, nine (38%) had one or more instances of a high androgen level, 92% had one or more instances of a high androgen level and/or the Ferriman-Gallwey (64) score ≥ 7, and 100% had one or more instances of a high androgen, and/or Ferriman-Gallwey score ≥ 7, and/or severe acne ( Table 2) .
Of the 24 women, 19 (79%) had pelvic ultrasound and/or laparotomy that documented polycystic ovaries ( Table 2 ). This allowed additional assessment of diagnosis of PCOS by the recent ESHRE/ASRM consensus criteria (67, 68) , requiring both the presence of polycystic ovaries and an elevated FAI (69) ( Table 2 ). Of the 17 women with documentation of polycystic ovaries and pre-treatment, pre-conception measurement of FAI, six (35%) would have been diagnosed as having PCOS by the newest criteria ( Table 2 , next to bottom row).
The cohort of women with PCOS was obese, with median weight 95.9 kg, and median BMI 34.1. Pre-gestation, pre-treatment, of the 24 women, four (17%) had BMI less than 25 (normal weight), four (17%) were overweight (BMI, 25 to 30), nine (38%) were obese (BMI, 30 to 40), and seven (29%) had extreme obesity (BMI ≥ 40) (73) . Of the 24 women, 75% had BMIs greater than or equal to the Lipid Research Clinics (1980) age-sex-specific 90th percentile (74) .
Median fasting serum insulin was high, 22 uU/mL. Fourteen (58%) of the women had high insulin levels (> 20 uU/mL). Insulin resistance (greater than or equal to the 90th percentile for 161 healthy normal female controls [≥ 5.54]) was present in 8/20 (40%) of the women. Beta cell function (insulin secretion) was high (≥ 361, the 90th percentile for 161 healthy normal female controls) in 6/20 (30%) of the women.
Pregnancy Outcomes
Of the 24 women, 23 had 65 previous pregnancies, with 18 live births, 46 SAB (71%), and one elective abortion. On metformin and enoxaparin, the same 23 women had 26 current pregnancies (28 fetuses), with 20 live births, two normal pregnancies of 13 weeks or longer, and six SAB (21%), 3.4-fold lower than previous gesta-tions, McNemar's S = 33.6, p < .0001 (Fig. 1) . The single patient without a previous pregnancy, and with known high anticardiolipin antibody IgG preceding gestation (no. 4, Table 1 ), uneventfully had one live birth on metformin and enoxaparin.
Based on our current observations, the current sample size had greater than 98% power to detect the difference in SAB rates between untreated pregnancy and metformin-enoxaparin treated pregnancy at significance level alpha = .05. In a placebo-controlled trial (placebo vs. metforminenoxaparin), with a power of 80% and alpha =. 05, 17 women would be needed in each group.
Of the 18 term live births, there were no significant differences in birth weight or length vs. gender-specific Centers for Disease Control normal population neonates (72) (p = 0.36 and 0.89 for girls' weight and height, p = 0.16 and 0.32 for boys' weight and height). There were no major congenital defects, and no neonatal or maternal hypoglycemia. One neonate (born to subject no. 4) had a tethered spinal cord.
On enoxaparin, there were no maternal thromboemboli, bleeding episodes, or thrombocytopenia.
DISCUSSION
As the number of thrombophilic and hypofibrinolytic risk factors increase in a single subject, the likelihood of developing first trimester miscarriage, major complications of pregnancy, and venous thromboembolism is increased (23, 24, 29, (75) (76) (77) (78) (79) . In the current study, cases, characterized by pregnancy loss, were more likely than controls to have heritable thrombophilia (high factor VIII, factor V Leiden heterozygosity) and hypofibrinolysis (4G4G polymorphism of the PAI-1 gene, high PAI-Fx). Congruent with findings of the current study, Rai noted that women who carry multiple thrombophilic defects are at the greatest risk for pregnancy loss (1). Preston and colleagues reported that the odds ratio for stillbirth was higher among women with combined thrombophilic defects (14.3 fold) compared to those with single defects (2-5.2 fold) (79) .
Separate from coagulation disorders, PCOS is associated with frequent first trimester miscarriage, which is sharply reduced by metformin (31) (32) (33) (34) 66) . Because of previous infertility and the heightened consequence of fetal loss in habitually infertile women with PCOS, in the cur-rent study of women with PCOS having one or more previous SAB or HELLP syndrome, we performed detailed pre-conception coagulation studies to identify possible causes of fetal loss. After conception on metformin (31) (32) (33) , in women with one or more coagulation disorders, we started enoxaparin (60 mg/day) as soon as pregnancy was verified, to optimize fetal survival beyond the protective effect of metformin (31) (32) (33) (34) . This was an observational pilot study. We recognized that an optimal design would have had a placebo for enoxaparin with all cases receiving metformin or, if feasible, a study with three placebo groups:
1. Double placebo (placebo-metforminplacebo-enoxaparin) 2. Placebo-metformin-active drug enoxaparin 3. Active drug metformin-placebo-enoxaparin 4. Active metformin and enoxaparin.
We did not have the patient resources to perform a placebo-controlled study with four patient groups, and wanted to develop sample and power size calculations for a subsequent metformin-enoxaparin placebo-controlled study. Based on our current observations, the current sample size had greater than 98% power to detect the difference in SAB rates between (previous) untreated pregnancies and metforminenoxaparin treated pregnancies at alpha = 0.05. In a placebo-controlled trial (placebo-placebo vs. metformin-enoxaparin), with a power of 80% and alpha =. 05, 17 women would be needed in each group.
In aggregate (1, 3, 23, 24, 41, 50) , when the thrombophilia of pregnancy (induced by physiologic hyperestrogenemia of pregnancy) is superimposed on pre-conception heritable thrombophilia and/or hypofibrinolysis, as in the present study, then there is a high level of fetal loss, particularly in women with PCOS who are likely to have hypofibrinolysis (23, 31, 35, (38) (39) (40) . Fetal loss during pregnancy in women with thrombophilia and/or hypofibrinolysis is probably caused by thrombotic occlusion of the spiral arteries of the uterus leading to placental insufficiency (1) .
Congruent with the findings of the current study, heterozygosity for the G1691A V Leiden mutation is a major risk factor for fetal loss (29) . Rai and colleagues (29) prospectively studied outcomes of untreated pregnancies among 25 women heterozygous for the factor V Leiden allele, 16 of whom had three or more SAB at less than 12 weeks' gestation in previous pregnan-cies, nine of whom previously had late SAB (>12 weeks gestation). Rai and colleagues also prospectively studied the outcomes of untreated pregnancies in 153 controls (without the V Leiden mutation) who had the same pattern of RPL or late SAB in previous pregnancies as the 25 women heterozygous for the V Leiden mutation (29) . There were live births in six of 16 (37.5%) current, untreated pregnancies in women with RPL (≥ 3 SAB <12 weeks) who had V Leiden heterozygosity, vs. 106 live births of 153 (69.3%) current pregnancies in the RPL controls (≥ 3 SAB < 12 weeks) without the V Leiden genotype (p < .05) (29) . In current untreated pregnancies, the live birth rate was 11.1% (1/9) among those with the V Leiden genotype and previous SAB at greater than 12 weeks vs. 48.9% (22/45) among those without the V Leiden genotype and previous SAB at greater than 12 weeks (29). Rai and colleagues concluded that ". . . Attention should be directed at screening women with recurrent miscarriage associated with placental thrombosis for Factor V Leiden and a policy of targeted thromboprophylaxis during future pregnancies should be assessed in the form of a randomized controlled trial" (29) .
Women with PCOS are not more likely than normal women to have resistance to activated protein C (47) or the V Leiden mutation (48) . Hence, our current study's factor V Leiden mutation enrichment, 17% in the cohort of 24 women with PCOS, vs. 2% in 93 normal white females, probably reflects factor V Leiden mutation's contribution to SAB and RPL (29) . In the current study, of the 24 women, 23 had 65 previous pregnancies, with 18 live births, 46 SAB (71%), and one elective abortion. On metformin and enoxaparin, these same 23 women had 26 current pregnancies (28 fetuses), with 20 live births, two normal pregnancies at 13 weeks or greater, and six SAB (21%), 3.4-fold lower than previous gestations (p < .0001). These fetal salvage benefits on current metformin and enoxaparin were achieved without maternal or fetal morbidity or mortality, without major birth defects, and with normal birth weight and length.
In future studies, the contribution of the fetal genotype in determining pregnancy outcome needs to be assessed (80) . The placenta receives two arterial supplies, one maternal, one fetal, and placental infarction should occur only if both vascular supplies are compromised (80) . Within this frame of reference, Dizon and colleagues reported that placental infarctions are more commonly seen when the fetus carried the factor V allele than if it was wild type normal (80) . In the current study, we were unable to obtain fetal tissue for DNA genotyping.
As in the current report, hypofibrinolysis associated with the 4G4G polymorphism of the PAI-1 gene and high levels of its gene product, PAI-Fx, also appear to play a significant role in SAB (31, (35) (36) (37) (38) and major complications of pregnancy in the second and third trimesters (23) . In women with severe complications of pregnancy (preeclampsia, abruption, fetal growth restrictions, stillbirth), Glueck and colleagues reported an increased incidence of the hypofibrinolytic 4G4G mutation of the PAI-1 gene, which, like the current study, was frequently accompanied by the V Leiden mutation (23). Dossenbach-Glaninger and colleagues have recently reported that 4G4G homozygosity is associated with early pregnancy loss (75) . Similar to findings in the current study where there was an enrichment of both the 4G4G PAI-1 gene mutation and high levels of PAI-Fx in cases vs controls, Glueck and colleagues previously reported that PAI-Fx is an independent risk factor for the high miscarriage rate in women with PCOS (38). Gris and colleagues reported that inhibitors of the fibrinolytic system are frequently abnormal in primary habitual aborters (36, 38) .
The common denominator for pregnancy complications seems to be placental insufficiency where insufficient invasion of trophoblasts and increased fibrin deposition are major pathologic components (81, 82) . Successful pregnancies require fine-tuning of fibrinolytic activities to secure fibrin polymerization and stabilization of the placental basal plate as well as to prevent excess fibrin deposition in placental vessels and intervillous spaces (81, 82) . Quenby and colleagues have postulated that recurrent miscarriage is result of failure of prevention of poor quality embryos implanting, allowing embryos to implant that are later destined to fail (83) .
Thromboprophylaxis with LMWH (41-46, 84-89) or unfractionated heparin (49) reduces pregnancy wastage vs. antecedent pregnancies without heparin therapy. Although the nonplacebo controlled trials of LMWH (41) (42) (43) (44) (45) (46) (84) (85) (86) (87) (88) (89) and unfractionated heparin (49) show striking improvement over previous pregnancies in the same women without thromboprophylaxis, the ultimate proof of safety and efficacy of thromboprophylaxis in women with RPL-SAB, thrombophilia, and hypofibrinolysis must be delivered by as-yet unreported, placebocontrolled clinical trials. In women with PCOS with one or more previous SAB or HELLP syndrome who also have thrombophilia and/or hypofibrinolysis, our current pilot study suggests that enoxaparin-metformin safely reduces pregnancy loss. Without placebo-enoxaparin, placebo-metformin, and placebo-placebo study arms accompanying enoxaparin-metformin in women with PCOS and one or more SAB or HELLP syndrome, we cannot determine the independent contributions of enoxaparin or metformin to fetal salvage.
